세계의 척추침 시장 예측(-2030년)

Market Overview

Spinal Needles Market is projected to register a healthy CAGR of 10.37% during the forecast period. The rising geriatric populace is inclined to spinal problems, and the rising predominance of spinal stenosis and neurological issues is driving the market development.

Spinal stenosis is an ailment portrayed by the pressure of nerve roots by a few neurotic variables connected with rope brokenness inspired by a mix of mechanical pressure and degenerative precariousness. The side effect of spinal stenosis incorporates shortcoming, torment, and deadness. An examination article distributed in the American Organization of Negligibly Obtrusive Medical procedure (AIMIS) in 2018 portrays that roughly 250,000-500,000 experience the ill effects of spinal stenosis addressing 1 for each 1000 people more established than 65 years and around 5 of each and every 1,000 people more seasoned than 50 years in America. This rising maturing populace experiencing spinal stenosis plainly requests a compelling careful mediation. Consequently, this component helps the market development of spinal needles.

Besides, a rising number of neurological issues likewise go about as a driving component for market development. As per the information distributed in Front Reach Spine and Neurosurgery in 2018, more than 600 neurological circumstances have been recognized, influencing many millions globally.

Market Segmentation

The Spinal Needles Market segmentation, based on type, includes pencil-point needles, and directional Based on an application the market is divided into therapeutic, and diagnostic. The Spinal Needles Market segmentation is based on end-user that includes hospitals & clinics, diagnostic centers, research laboratories, and others.

Regional Insights

The Europe Leavening Agents market represented USD 31,613.76 million in 2021 and is supposed to display a 6.04% CAGR during the review time frame. the rising inclination for clean-name fixings and the quick development of the bread kitchen industry is projected to introduce rewarding development and venture valuable open doors for market players during the survey time frame.

Besides, the German leavening agents market held the biggest piece of the pie, and the France leavening agents market was the quickest developing business sector in the European region.

North America's leavening agents market represents the second-biggest piece of the pie because of the Rising interest in regular food fixings. Further, the US leavening agents market held the biggest piece of the pie, and the Canadian leavening agents market likewise holds a huge piece of the pie in the North American region.

The Asia-Pacific leavening agents market is supposed to develop at a CAGR of 7.07% from 2022 to 2030. This is because of changing purchaser dietary propensities for different applications. Also, the China leavening agents market held the biggest piece of the pie, and the India leavening agents market was the quickest developing business sector in the Asia-Pacific region.

Major Players

Key Companies in the Spinal Needles Market Include Boston Scientific Corporation (US), Stryker Corporation (US), Becton, Braun Melsungen AG (US), Smith's Medical (US), Myco Medical (US), Dickinson, and Company (US), Argon Medical (US), and Exelint International, Co. (US).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 SCOPE OF THE STUDY
• 2.2 RESEARCH OBJECTIVE
• 2.3 MARKET STRUCTURE
• 2.4 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING
• 3.2 SECONDARY RESEARCH
• 3.3 PRIMARY RESEARCH
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS
• 3.5 FORECASTING TECHNIQUES
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
  • 3.6.1 BOTTOM-UP APPROACH
  • 3.6.2 TOP-DOWN APPROACH
• 3.7 DATA TRIANGULATION
• 3.8 VALIDATION

4 MARKET DYNAMICS

• 4.1 OVERVIEW
• 4.2 DRIVERS
  • 4.2.1 INCREASING PREVALENCE OF SPINAL STENOSIS AND NEUROLOGICAL DISORDERS
  • 4.2.2 RISING GERIATRIC POPULATION PRONE TO SPINAL DISORDERS
  • 4.2.3 INCREASING APPLICATION OF SPINAL NEEDLES FOR SPINE SURGERIES
• 4.3 RESTRAINTS
  • 4.3.1 SIDE EFFECTS AND COMPLICATIONS ASSOCIATED WITH SPINE SURGERY
  • 4.3.2 STRINGENT GOVERNMENT REGULATIONS
• 4.4 OPPORTUNITIES
  • 4.4.1 INCREASING NUMBER OF COLLABORATIONS, ACQUISITIONS, AND PRODUCT LAUNCHES

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 R&D AND DESIGNING
  • 5.1.2 MANUFACTURING
  • 5.1.3 DISTRIBUTION, MARKETING, & SALES
  • 5.1.4 POST-SALES MONITORING
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 BARGAINING POWER OF SUPPLIERS
  • 5.2.3 THREAT OF SUBSTITUTES
  • 5.2.4 BARGAINING POWER OF BUYERS
  • 5.2.5 INTENSITY OF RIVALRY
• 5.3 COVID-19 IMPACT ANALYSIS
  • 5.3.1 IMPACT ON SPINAL SURGERY
  • 5.3.2 IMPACT ON SPINE SURGEONS
  • 5.3.3 IMPACT ON CLINICAL TRIALS

6 GLOAL SPINAL NEEDLES MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 ATRAUMATIC NEEDLES
• 6.3 DIRECTIONAL SPINAL NEEDLES
• 6.4 PENCIL-POINT NEEDLES

7 GLOBAL SPINAL NEEDLES MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 THERAPEUTIC
• 7.3 DIAGNOSTIC

8 SPINAL NEEDLES MARKET, BY END USER

• 8.1 OVERVIEW
• 8.2 HOSPITALS & CLINICS
• 8.3 DIAGNOSTIC CENTERS
• 8.4 RESEARCH LABORATORIES
• 8.5 SPECIALTY CENTERS

9 GLOBAL SPINAL NEEDLES MARKET, BY REGION

• 9.1 OVERVIEW
• 9.2 AMERICAS
  • 9.2.1 NORTH AMERICA
    • 9.2.1.1 US
    • 9.2.1.2 CANADA
  • 9.2.2 LATIN AMERICA
• 9.3 EUROPE
  • 9.3.1 WESTERN EUROPE
    • 9.3.1.1 GERMANY
    • 9.3.1.2 FRANCE
    • 9.3.1.3 UK
    • 9.3.1.4 ITALY
    • 9.3.1.5 SPAIN
    • 9.3.1.6 REST OF WESTERN EUROPE
  • 9.3.2 EASTERN EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 CHINA
  • 9.4.2 INDIA
  • 9.4.3 JAPAN
  • 9.4.4 SOUTH KOREA
  • 9.4.5 AUSTRALIA
  • 9.4.6 REST OF ASIA PACIFIC
• 9.5 MIDDLE EAST & AFRICA
  • 9.5.1 MIDDLE EAST
  • 9.5.2 AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW
• 10.2 COMPETITIVE BENCHMARKING
• 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL SPINAL NEEDLES MARKET
• 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL SPINAL NEEDLES MARKET
• 10.5 KEY DEVELOPMENT ANALYSIS
• 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.6.1 PRODUCT LAUNCH/PRODUCT APPROVAL
  • 10.6.2 MERGER/ACQUISITION
  • 10.6.3 EXPANSION/INVESTMENT
• 10.7 FINANCIAL MATRIX
  • 10.7.1 SALES (USD MILLION) AND OPERATING PROFIT MARGIN (%), 2020
  • 10.7.2 R&D EXPENDITURE (USD MILLION), 2020

11 COMPANY PROFILES

• 11.1 STRYKER CORPORATION
  • 11.1.1 COMPANY OVERVIEW
  • 11.1.2 FINANCIAL OVERVIEW
  • 11.1.3 PRODUCTS OFFERED
  • 11.1.4 KEY DEVELOPMENTS
  • 11.1.5 SWOT ANALYSIS
  • 11.1.6 KEY STRATEGIES
• 11.2 BOSTON SCIENTIFIC CORPORATION
  • 11.2.1 COMPANY OVERVIEW
  • 11.2.2 FINANCIAL OVERVIEW
  • 11.2.3 PRODUCTS/SERVICES OFFERED
  • 11.2.4 KEY DEVELOPMENTS
  • 11.2.5 SWOT ANALYSIS
  • 11.2.6 KEY STRATEGIES
• 11.3 B. BRAUN MELSUNGEN AG
  • 11.3.1 COMPANY OVERVIEW
  • 11.3.2 FINANCIAL OVERVIEW
  • 11.3.3 PRODUCTS/SERVICES OFFERED
  • 11.3.4 KEY DEVELOPMENTS
  • 11.3.5 SWOT ANALYSIS
  • 11.3.6 KEY STRATEGIES
• 11.4 MEDTRONIC PLC
  • 11.4.1 COMPANY OVERVIEW
  • 11.4.2 FINANCIAL OVERVIEW
  • 11.4.3 PRODUCTS/SERVICES OFFERED
  • 11.4.4 KEY DEVELOPMENTS
  • 11.4.5 SWOT ANALYSIS
  • 11.4.6 KEY STRATEGIES
• 11.5 SMITHS MEDICAL
  • 11.5.1 COMPANY OVERVIEW
  • 11.5.2 FINANCIAL OVERVIEW
  • 11.5.3 PRODUCTS/SERVICES OFFERED
  • 11.5.4 KEY DEVELOPMENTS
  • 11.5.5 SWOT ANALYSIS
  • 11.5.6 KEY STRATEGIES
• 11.6 BECTON, DICKINSON, AND COMPANY
  • 11.6.1 COMPANY OVERVIEW
  • 11.6.2 FINANCIAL OVERVIEW
  • 11.6.3 PRODUCTS OFFERED
  • 11.6.4 KEY DEVELOPMENTS
  • 11.6.5 SWOT ANALYSIS
  • 11.6.6 KEY STRATEGIES
• 11.7 EXELINT INTERNATIONAL, CO.
  • 11.7.1 COMPANY OVERVIEW
  • 11.7.2 FINANCIAL OVERVIEW
  • 11.7.3 PRODUCTS OFFERED
  • 11.7.4 KEY DEVELOPMENTS
  • 11.7.5 SWOT ANALYSIS
  • 11.7.6 KEY STRATEGIES
• 11.8 ARGON MEDICAL
  • 11.8.1 COMPANY OVERVIEW
  • 11.8.2 FINANCIAL OVERVIEW
  • 11.8.3 PRODUCTS OFFERED
  • 11.8.4 KEY DEVELOPMENTS
  • 11.8.5 SWOT ANALYSIS
  • 11.8.6 KEY STRATEGIES
• 11.9 MYCO MEDICAL
  • 11.9.1 COMPANY OVERVIEW
  • 11.9.2 FINANCIAL OVERVIEW
  • 11.9.3 PRODUCTS OFFERED
  • 11.9.4 KEY DEVELOPMENTS
  • 11.9.5 SWOT ANALYSIS
  • 11.9.6 KEY STRATEGIES
• 11.10 COOK MEDICAL
  • 11.10.1 COMPANY OVERVIEW
  • 11.10.2 FINANCIAL OVERVIEW
  • 11.10.3 PRODUCTS OFFERED
  • 11.10.4 KEY DEVELOPMENTS
  • 11.10.5 SWOT ANALYSIS
  • 11.10.6 KEY STRATEGIES

12 APPENDIX

• 12.1 REFERENCES
• 12.2 RELATED REPORTS